Production and verification of human papillomavirus type 18 vaccine in vitro

Oncology Reports

Volumn 20, Issue 1, 2008, Pages 211-217

  Liao, Shujie ^a   Wang, Shixuan ^a   Xu, Ling ^a   Deng, Dongrui ^a   Xu, Qian ^a   Wang, Wei ^a   Zhu, Tao ^a   Bai, Xiangyang ^a   Zhou, Jianfeng ^a   Xu, Gang ^a   Lu, Yunping ^a   Meng, Li ^a   Ma, Ding ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bac to Bac baculovirus expression system; Enzyme linked immunospot; Human papillomavirus type 18; Virus like particles

Indexed keywords

GAMMA INTERFERON; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS TYPE 18 L1 VLP VACCINE;

ANIMAL CELL; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CELL NUCLEUS; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HEMAGGLUTINATION TEST; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 18; HYPOTHESIS; IMMUNE RESPONSE; IMMUNITY; IMMUNOREACTIVITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PURIFICATION; VACCINE PRODUCTION; VIRUS LIKE AGENT; ANIMAL; ARMYWORM; BIOSYNTHESIS; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL CULTURE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MOUSE; POLYMERASE CHAIN REACTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HEMAGGLUTINATION TESTS; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS VACCINES; POLYMERASE CHAIN REACTION; SPODOPTERA;

EID: 49849097264     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.20.1.211     Document Type: Article

References (32)

1. Kesic VB and Ostojic N: Etiopathogenesis of premalignant cervical conditions [in Serbian]. Abstract Book of Symposium of Premalignant Conditions and Cervical Cancer. pp21-30, 1996.
2. zur Hausen H: Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92: 690-698, 2000.
3. Zhou J, Sun XY, Stenzel DJ and Frazer IH: Expression of vaccinia recombinant HPV16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185: 251-257, 1991.
4. Lowy DR and Schiller JT: Prophylactic human papillomavirus vaccines. J Clin Invest 116: 1167-1173, 2006.
5. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2002: Cancer incidence, mortality and prevalence world wide [C] IARC Cancer Base No. 5, version 2.0. IARC Press, Lyon, 2004.
6. Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, Pan QJ, Fischer C, Lorincz A and Zahniser D: Shanxi Province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 84: 355, 2002.
7. Gibco B: Instruction manual of Bac-To-Bac baculovirus expression systems. Producer of Gibco BRL Products, 2004.
8. Montross L, Watkins S, Moreland RB, Mamon H, Caspar DL and Garcea RL: Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VP1. J Virol 65: 4991-4998, 1991.
9. Roden RB, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR and Schiller JT: Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol 69: 5147-5151, 1995.
10. Reddy KJ, Banapour B, Anderson DE, Lee SH, Marquez JP, Carlos MP and Torres JV: Induction of immune responses against human papillomaviruses by hypervariable epitope constructs. Immunology 112: 321-327, 2004.
11. Sacerdote P, Rubboli F, Locatelli L, Ciciliato I, Mantegazza P and Panerai AE: Pharmacological modulation of neuropeptides in peripheral mononuclear cells. J Neuroimmunol 32: 35-41, 1991.
12. Liu HW, Hong KX, Ma J, Yuan L, Liu S, Chen JP, Zhang YZ, Ruan YH, Xu JQ and Shao YM: Identification of HIV-1 specific T lymphocyte responses in highly exposed persistently sero-negative Chinese. Chin Med J 119: 1616-1621, 2006.
13. Vazquez-Ortiz G, Ciudad CJ, Pina P, Vazquez K, Hidalgo A, Alatorre B, Garcia JA, Salamanca F, Peralta-Rodriguez R, Rangel A and Salcedo M: Gene identification by cDNA arrays in HPV-positive cervical cancer. Arch Med Res 36: 448-458, 2005.
14. Cools N, Ponsaerts P, Lenjou M, Nijs G, Van Bockstaele DR, Van Tendeloo VF and Berneman ZN: Sensitive detection of human papillomavirus type 16 E7-specific T cells by ELISPOT after multiple in vitro stimulations of CD8+ T cells with peptide-pulsed autologous dendritic cells. Mol Cancer 5: 49, 2006.
15. Klug A and Finch JT: Structure of viruses of the papillomapolyoma type. I. Human wart virus. J Mol Biol 11: 403-423, 1965.
16. Rose RC, Bonnez W, Reichman RC and Garcea RL: Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus-like particles. J Virol 67: 1936-1944, 1993.
17. Pagliusi S: Human papillomavirus infection and cervical cancer. World Health Organization http://www.who.int/vaccine_research/diseases/hpv/en/. 2006, October 26.
18. Franco EL, Rohan TE and Villa LL: Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91: 506-511, 1999.
19. Bosch F, Lorincz A, Muñoz N, Meijer C and Shah K: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244-265, 2002.
20. Villa LL: Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine 24: S23-S28, 2006.
21. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM, Ades T, Andrews KS, Doroshenk MX, Kahn KG, Schmidt C, Shafey O, Smith RA, Partridge EE, Gynecologic Cancer Advisory Group and Garcia F: American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57: 7-28, 2007.
22. Trus BL, Roden RB, Greenstone HL, Vrhel M, Schiller JT and Booy FP: Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nat Struct Biol 4: 413-420, 1997.
23. O'Reilly DR: Use of baculovirus expression vectors. Methods Mol Biol 62: 235-246, 1997.
24. Stanley M, Lowy DR and Frazer I: Chapter 12: Prophylactic HPV vaccines: Underlying mechanisms. Vaccine 24: S106-S113, 2006.
25. Cheng WF, Hung CF, Hsu KF, Chai CY, He L, Polo JM, Slater LA, Ling M and Wu TC: Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 13: 553-568, 2002.
26. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Rice CM, Ling M and Wu TC: Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol 166: 6218-6226, 2001.
27. Cheng WF, Hung CH, Chai CY, Hsu KF, He L, Ling M and Wu TC: Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol 75: 2368-2376, 2001.
28. Cheng WF, Lee CN, Su YN, Chang MC, Hsiao WC, Chen CA and Hsieh CY: Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology 115: 136-149, 2005.
29. Orozco JJ, Carter JJ, Koutsky LA and Galloway DA: Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 11 capsomers. J Virol 79: 9503-9514, 2005.
30. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE and Rose RC: Immunological analyses of human papillomavirus capsids. Vaccine 19: 1783-1793, 2001.
31. Fleury MJ, Touze A, Alvarez E, Carpentier G, Clavel C, Vautherot JF and Coursaget P: Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol 151: 1511-1523, 2006.
32. Combita AL, Touzé A, Bousarghin L, Christensen ND and Coursaget P: Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76: 6480-6486, 2002.